GNLX.US Genelux Corporation Common Stock

Healthcare Biotechnology USA Stocks
1.87 USD
Close of Nov 13, 2026
1.77 5.89
Market cap
USD 84.4M
P/E
-
P/B
5.31x
ROE
-206.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GNLX.US undervalued?

Graham number

The Graham number of Genelux Corporation Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genelux Corporation Common Stock fundamental analysis

No fundamental analysis for Genelux Corporation Common Stock yet.

Genelux Corporation Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genelux Corporation Common Stock

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive libr…

Full company profile